KCT0003992进行中（未招募）未知
Efficacy and Safety of HU033 on prostate gland health; A 12week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial
Huons0 个研究点目标入组 135 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 40(Year) 至 75(Year)（—）
- 性别
- Male
入选标准
- •1) Men over 40 years old and under 75 years of age
- •2) International Prostate Symptom Score (IPSS) in the range of 8 to 19)
- •3) Those who agree to participate in the human aptitude test and who have completed a written consent form prior to the commencement of the Clinical trial
排除标准
- •1) A person currently being treated for clinically significant acute or chronic cardiovascular relationships, immune systems, respiratory systems, gingko systems, kidney and urinary machinery, nervous systems, musculoskeletal disorders, psychotropic, infectious and blood and tumor diseases (however, it is possible to participate in the test according to the judgment of the test taker.)
- •2) Those with a blood prostate specific antigen (PSA) concentration greater than 4.0ng/ml (but those who have confirmed non-cancer test results within three months prior to this human testing can register)
- •3) Those with a maximum urination rate of less than 5 ml/s
- •4) Those who have a residual amount of more than 150 ml
- •5) bladder tumor, urinary stones, urethral stenosis, bladder construction, lower urinary tract (breathing, urethra) inflammation, urinary tuberculosis disease
- •6) A person diagnosed with prostate cancer
- •7) Persons who have undergone an invasive procedure for urinary tract-related surgery, including prostate surgery, and other prostate treatments
- •8) Patients with unregulated hypertension (160/100mmHg or higher, measured after 10 minutes of stabilization of the test subjects)
- •9) Unregulated diabetic patients (in case of new drug initiation due to diabetes within 3 months or greater than 180 mg/dl per empty blood)
- •10) a person with thyroid disease
- •11) Those whose creatine is more than twice the normal upper limit of the test institution
- •12) A person whose AST (GOT) or ALT (GPT) is more than three times the normal upper limit of the testing agency.
- •13) ?? ?? 4? ??? ??? ??? ??? ? ??????? ??? ?
- •14) Persons who participated in another clinical trial within three months prior to this human testing or who plan to participate in another clinical trial during this human testing period
- •15) Persons who are sensitive or allergic to food related to Quisqualis indica
- •16) who the Investigation finds inappropriate for this human testing.
研究者
相似试验
尚未招募
不适用
Efficacy and safety of HT080 on prostate gland health: a 12-week, randomized, double-blind, placebo-controlled clinical trial.KCT0004286EUMED100
已完成
不适用
Efficacy and Safety of HN-550M on prostate gland health; A 12week Clinical TrialKCT0006699Curome Biosciences135
招募中
不适用
A Clinical Trial for Efficacy and Safety of PSE on prostate gland healthKCT0004316Chung-Ang Univerisity Hospital100
尚未招募
不适用
Evaluation of safety and efficacy in prostate cancer patients treated with focal low-dose-rate brachytherapyProstate cancerJPRN-UMIN000030509Kitasato University School of Medicine, Department of Urology20
招募中
不适用
Evaluation of therapeutic effect on prostate cancer patients with bone metastases using Bone Scan Index (BSI)Prostate cancer patients with bone metastasisJPRN-UMIN000011648Osaka University160